Athira Pharma Inc

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegradation. Its pipeline includes ATH-1105 for amyotrophic lateral sclerosis and ATH-1020 for neurodegenerative diseases, both in Phase 1 clinical trials, as well as early compounds in preclinical phases. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. It was incorporated in 2011 and is headquartered in Bothell, Washington.